↓ Skip to main content

Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

Overview of attention for article published in BMC Musculoskeletal Disorders, May 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
Published in
BMC Musculoskeletal Disorders, May 2015
DOI 10.1186/s12891-015-0587-1
Pubmed ID
Authors

Mahmood M. T. M. Ally, Bridget Hodkinson, Pieter W. A. Meyer, Eustasius Musenge, Gregory R. Tintinger, Mohammed Tikly, Ronald Anderson

Abstract

To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. A cohort of 140 predominantly (88.5 %) black female South African patients with early RA was treated with synthetic DMARDs, mostly methotrexate (MTX) alone, or in combination with low-dose oral corticosteroids (CS). Circulating ACPA and a panel of circulating cytokines/chemokines/growth factors were measured at baseline and after 6 months of therapy in relation to disease activity and Shared Epitope (SE). Following 6 months of therapy, the median simplified disease activity index (SDAI) declined from a baseline of 41.4 to 16.0 (p = 0.0001) for the entire cohort, which was paralleled by significant falls in median serum ACPA levels (516.6 vs. 255.7 units/ml, p = <0.0001) and several of the circulating cytokines (IL-4, IL-7, IL-8, G-CSF, VEGF; p < 0.0010 - p < 0.0001) which were most evident in the subgroup of patients treated with a combination of MTX and CS. Although biomarker concentrations decreased most notably in the low-disease activity group post-therapy, no significant correlations between these biomarkers and disease activity were observed, Baseline ACPA levels, but not SDAI or cytokines, were significantly higher in the subgroup of risk allele-positive patients (561.1 vs. 331.9 units/ml, p < 0.05), while no associations with ACPA and a smoking history were evident. The use of DMARDs in RA is associated with significant decreases in ACPA and cytokines which did not correlate with changes in SDAI, precluding the utility of serial measurement of these biomarkers to monitor early responses to therapy, but may have prognostic value.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 2%
Netherlands 1 2%
Sweden 1 2%
United Kingdom 1 2%
Canada 1 2%
Unknown 51 91%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 21%
Student > Ph. D. Student 7 13%
Researcher 7 13%
Student > Postgraduate 5 9%
Student > Bachelor 4 7%
Other 12 21%
Unknown 9 16%
Readers by discipline Count As %
Medicine and Dentistry 15 27%
Pharmacology, Toxicology and Pharmaceutical Science 7 13%
Immunology and Microbiology 6 11%
Biochemistry, Genetics and Molecular Biology 4 7%
Nursing and Health Professions 2 4%
Other 9 16%
Unknown 13 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2015.
All research outputs
#4,294,624
of 5,165,331 outputs
Outputs from BMC Musculoskeletal Disorders
#1,572
of 1,725 outputs
Outputs of similar age
#141,913
of 172,831 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#49
of 52 outputs
Altmetric has tracked 5,165,331 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,725 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,831 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.